Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
NCT ID: NCT01255124
Last Updated: 2011-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1297 participants
OBSERVATIONAL
2010-10-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mother-to-child Transmission of HBV in China
NCT05172453
Evaluation of Immunoprotection Provided by Hepatitis B Vaccine After Birth in Healthy Children
NCT04439435
Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong
NCT02443233
Early Waning of Maternal Measles and Meningitis C Antibodies
NCT02219061
A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus (HBV MTCT)in Newborns at High Risk
NCT02901418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Infections of Hand, Foot and Month Disease in infants and young children may lead to a certain proportion of serious cases with various complications or death. The primary aim of this study is to find dynamic changes of the maternal anti-EV71 antibody in infants and young children and to provide basic data for the future application of EV71 vaccines. The second aim of this study is to find dynamic changes of the maternal anti- CVA16 antibody levels in infants and young children The third aim of this study is to discover the risk factors of Hand, Foot and Month Disease and to estimate the burden of disease.Hand, Foot and Mouth Disease(HFMD)is a common infectious disease in infants and young children caused by enterovirus. Since 2008, HFMD has become one of the category c infectious diseases in China. However a group of picornavirus of enterovirus can caused HFMD, including coxsackievirus A (CVA), coxsackievirus B(CVB), Human Enterovirus 71(EV71), Echovirus(ECHO) and so on, EV71 and CVA16 are the most common reason for this disease. This study is carried out to discover dynamic changes of the maternal anti-EV71 and ant-CVA16 in infants and young children from this study.
Infections of Hand, Foot and Month Disease in infants and young children may lead to a certain proportion of serious cases with various complications or death. The primary aim of this study is to find dynamic changes of the maternal anti-EV71 in infants and young children and to provide basic data for the future application of EV71 vaccines. The second aim of this study is to find dynamic changes of the maternal anti-CVA16 levels in infants and young children. The third aim of this study is to discover the risk factors of Hand, Foot and Month Disease and to estimate the burden of disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health infants (ClinicalTrials.gov ID: NCT01183611)
The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent obtained from the parent(s) of the subject.
* Subjects who the investigator believes will comply with the requirements of the protocol.
Exclusion Criteria
* Major congenital defects or serious chronic illness.
* Maldevelopment
* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
2 Years
3 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Province Centers for Disease Control and Prevention
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Feng-cai Zhu, Master
Role: PRINCIPAL_INVESTIGATOR
Jiangsu Provincial Center for Diseases Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSVCT002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.